- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A pharmacist said an Almirall COPD guidelines meeting invite blurred education vs promotion. PMCPA ruled the invite/meeting were clearly promotional launch activity,…
Sanofi’s Lyxumia leavepiece claimed lower GLP-1 prescribing costs. PMCPA accepted acquisition-cost comparisons in principle, but ruled the Bydureon comparison misleading (needles excluded;…
Pfizer challenged a GSK Votrient leavepiece for allegedly misleading presentation of COMPARZ non-inferiority data (ITT vs PP) and a PISCES patient-preference claim.…
Companies sponsored a BJMA UK meeting with limited scientific content and extensive family/social activities. Panel found breaches for Lundbeck, Menarini and Bayer;…
Anonymous complaint upheld in part: Pharmaxis failed to certify final promotional materials pre-Aug 2013 and mishandled certification/categorisation of a sponsored CF journal…
Roche alleged Merck Serono breached a prior PMCPA undertaking via a Cancer Drugs Fund presentation of Erbitux trial data. The Panel found…
Anonymous complaint alleged GSK’s SUMMIT study press release was misleading (use of “survival”, 12.2% lower risk of dying) and omitted the black…
A payer-targeted email highlighted a 29% allopurinol price rise and implied Adenuric could help manage long-term costs. PMCPA found the material misleading…
Daiichi Sankyo’s publicly accessible forum website synopsis for an “advance budgetary notification” workshop about an unlicensed anticoagulant (edoxaban) was ruled insufficiently targeted,…
A ‘safety’ letter about Navelbine Oral dosing was ruled promotional. Missing prescribing info and AE reporting, an unqualified indication, and misleading/unsupported efficacy-survival…
An NHS chief pharmacist alleged a Strattera nurse speaker contract looked like inducement/seeding research and queried disclosure. PMCPA found misunderstanding from wording…
Public complaint about clinical trial transparency data. Panel found delayed disclosure for one UK-involved Mozobil trial (breach Clauses 9.1, 21.3). Renvela issues…
Anonymous complaint alleged excessive hospitality and poor rep conduct at a Novartis-sponsored restaurant meeting. Panel said costs/drinks were at the outer limits…
A sevoflurane packaging “drop test” leaflet was ruled promotional. It omitted the medicine’s cost, the mandatory adverse event reporting statement and the…
Anonymous complaint alleged GSK promoted an unlicensed malaria vaccine to the public via a Telegraph Online ad. PMCPA ruled the 30-second video…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.